Tag Archives: AGIO

Friday’s Highlights at Noon: El Pollo LoCo (LOCO), United States Steel (X), Agios Pharma (AGIO), Aerie Pharma (AERI), Rite Aid Corp (RAD)

So far Friday, November 1, NASDAQ is up 0.71% and the S&P is up 0.71%. Here are this morning’s most active stocks: El Pollo LoCo (LOCO – Research Report), United States Steel (X – Research Report), Agios Pharma (AGIO –

Agios Pharma (AGIO) Receives a Buy from Needham

Needham analyst Chad Messer maintained a Buy rating on Agios Pharma (AGIO – Research Report) today and set a price target of $71.00. The company’s shares closed last Monday at $29.95, close to its 52-week low of $29.08. According to

Monday’s Midday Movers: Agios Pharma (AGIO), Arrowhead Research (ARWR), Novavax (NVAX), Heron Therapeutics (HRTX), Pacira Pharmaceuticals (PCRX)

So far Monday, September 30, NASDAQ is up 2.04% and the S&P is up 1.39%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Agios Pharma (AGIO – Research Report), Arrowhead Research (ARWR –

The CSO of Agios Pharma is Exercising Options

Today it was reported that the CSO of Agios Pharma (AGIO – Research Report), Scott Biller, exercised options to buy 7,218 AGIO shares at $2.33 a share, for a total transaction value of $16.82K. Following this transaction Scott Biller’s holding

Thursday’s Highlights at Noon: NovaBay Pharma (NBY), Kandi Technologies (KNDI), AVEO Pharma (AVEO), Agios Pharma (AGIO), OncoSec Medical (ONCS)

So far Thursday, May 16, NASDAQ is up 4.23% and the S&P is up 2.81%. Here are this morning’s most active stocks: NovaBay Pharma (NBY – Research Report), Kandi Technologies (KNDI – Research Report), AVEO Pharma (AVEO – Research Report),

Thursday’s Midday Movers: American Green Inc (ERBB), NovaBay Pharma (NBY), AVEO Pharma (AVEO), Kandi Technologies (KNDI), Agios Pharma (AGIO)

So far Thursday, May 16, NASDAQ is up 4.23% and the S&P is up 2.85%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), NovaBay Pharma (NBY